William J. Link PhD - 25 Jun 2026 Form 4 Insider Report for Tarsus Pharmaceuticals, Inc. (TARS)

Reporting relationship: Director
Issuer ticker: TARS
Reported as of: 25 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 29 Jun 2026, 16:30:42 UTC
Prior SEC filing: 18 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Scott Sieckert, Attorney-in-Fact

Key filing fact

William J. Link PhD filed Form 4 for Tarsus Pharmaceuticals, Inc. (TARS) on 29 Jun 2026.

Key facts

This page summarizes William J. Link PhD's Form 4 filing for Tarsus Pharmaceuticals, Inc. (TARS).
3 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 29 Jun 2026, 16:30.

Change

Previous filing in this sequence was filed on 18 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001228684 Primary reporting owner

LINK WILLIAM J PHD

Relationship: Director
Address: C/O TARSUS PHARMACEUTICALS, INC., 17700 LAGUNA CANYON ROAD, FLOOR 4, IRVINE
Signature: /s/ Scott Sieckert, Attorney-in-Fact
Signature date: 29 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TARS transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +3,837
Change %
Price: $0.000000^*
Shares after: 3,837
Date: 25 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 3,837
Exercise price: $64.34
Footnotes: F1

TARS transaction Derivative

Restricted Stock Units

Award

Transaction value
Shares: +2,417
Change %
Price: $0.000000^*
Shares after: 2,417
Date: 25 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2,417
Exercise price
Footnotes: F2, F3

TARS transaction Derivative

Restricted Stock Units

Award

Transaction value
Shares: +806
Change %
Price: $0.000000^*
Shares after: 806
Date: 25 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 806
Exercise price
Footnotes: F2, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.

Footnote F2

Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock.

Footnote F3

RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.

Footnote F4

RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in equal installments on 9/15/2026, 12/15/2026, 3/15/2027 and 6/15/2027, subject to the non-employee director's continuous service.